Barr Pharmaceuticals Receives Final Approval For Generic Mirapex Tablets - Quick Facts

(RTTNews) - Barr Pharmaceuticals Inc. (BRL | news | PowerRating | PR Charts ) announced that its subsidiary, Barr Laboratories Inc., has received final approval from the U.S. Food and Drug Administration for its generic version of Boehringer Ingelheim Pharmaceuticals Inc.'s Mirapex Tablets (Pramipexole Dihydrochloride) 0.125mg, 0.25mg, 0.5mg, 1mg & 1.5mg.

Barr's Pramipexole Dihydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.

The Company is currently challenging a patent protecting Mirapex and a trial is scheduled to begin on March 10, 2008 in the District Court in Delaware.

Under the terms of a Court Order, Barr has agreed not to launch its Pramipexole Dihydrochloride tablets product until the earliest of the following occurs: 90 days following the conclusion of the presentation of evidence in the District Court trial, the date a favorable judgment for Barr is entered by the District Court, or July 14, 2008.

For comments and feedback: contact editorial@rttnews.com Copyright(c) 2008 RealTimeTraders.com, Inc. All Rights Reserved

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index